Lepu Biopharma Co., Ltd. (HKG:2157)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.810
+0.110 (2.97%)
Jun 18, 2026, 4:08 PM HKT
Market Cap6.68B -12.9%
Revenue (ttm)1.04B +154.2%
Net Income290.85M
EPS0.17
Shares Out 1.80B
PE Ratio22.33
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,038,000
Open3.720
Previous Close3.700
Day's Range3.660 - 3.890
52-Week Range3.550 - 10.500
Beta-0.44
AnalystsStrong Buy
Price Target11.02 (+189.24%)
Earnings DateMar 25, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 710
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2157
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements